Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12886381 | 0.92 | GSK3B (0.52) | GSK3BAAK1HDAC6CYP1A2GSK3A | |
| SCHEMBL4480187 | 0.90 | GSK3B (0.59) | GSK3BHDAC6CYP1A2FGFR1FGFR2 | |
| SCHEMBL4558529 | 0.90 | GSK3B (0.65) | GSK3BAAK1HDAC6CYP1A2GSK3A | |
| SCHEMBL4488734 | 0.89 | GSK3B (0.53) | GSK3BAAK1HDAC6CYP1A2GSK3A | |
| SCHEMBL4498152 | 0.88 | GSK3B (0.52) | GSK3BAAK1HDAC6CYP1A2GSK3A | |
| SCHEMBL4502574 | 0.88 | GSK3B (0.57) | GSK3BHDAC6CYP1A2FGFR1FGFR2 | |
| SCHEMBL4488792 | 0.88 | AAK1 (0.68) | GSK3BAAK1CYP1A2FGFR2FGFR3 | |
| SCHEMBL4505096 | 0.88 | GSK3B (0.51) | GSK3BAAK1HDAC6CYP1A2GSK3A | |
| SCHEMBL4487384 | 0.87 | HDAC1 (0.64) | AAK1HDAC6CYP1A2FGFR1FGFR2 | |
| SCHEMBL4494405 | 0.87 | GSK3B (0.55) | GSK3BAAK1HDAC6CYP1A2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632854-B2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-12-15 | — | — | US | claimed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | GSK3B 5/4885AAK1 441/4885HDAC6 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.